Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ISOLDA

Financiado

Cerrado

Improved Vaccination Strategies for Older Adults

ISOLDA aims at the development of improved vaccines for older adults against viral diseases with highest burdens at old age, by promoting virus-specific T cell responses in vaccinees over 65 years, using modulators of T cell immun... ver más

31/12/2024

STIFTUNG TIERAERZT...

6M€

Presupuesto del proyecto: 6M€

Líder del proyecto

STIFTUNG TIERAERZTLICHE HOCHSCHULE HANNOVER No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 7 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-12-31

SC1-BHC-14-2019: Stratified host-directed approaches...

I+D

Cerrada hace 6 años

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

7 Participantes

STIFTUNG TIERAERZTLICHE HOCH...

1.71M€ | Lider

FUNDACIÓN PÚBLICA MIGUEL SER...

500.00K€ | Participante

ERASMUS MC

400.00K€ | Participante

BNI

650.55K€ | Participante

Proyectos interesantes

TWILIGHT

Medical Technol...

Immunology

1M€ Cerrado

IRINVAC

Medical Technol...

Public Health

100K€ Cerrado

PTQ-09-02-01876

Medical Technol...

Vaccinology

24K€ Cerrado

RYC2020-028934-I

Medical Technol...

Immunology

324K€ Cerrado

BES-2014-067753

Medical Technol...

Vaccinology

88K€ Cerrado

JCI-2011-09963

Medical Technol...

Immunology

96K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 60 meses Fecha Inicio: 2019-12-12
Fecha Fin: 2024-12-31

Líder del proyecto

STIFTUNG TIERAERZTLICHE HOCHSCHULE HANNOVER No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 6M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto ISOLDA aims at the development of improved vaccines for older adults against viral diseases with highest burdens at old age, by promoting virus-specific T cell responses in vaccinees over 65 years, using modulators of T cell immunosenescence and inflammageing. It builds on leading interdisciplinary expertise and knowledge of ISOLDA partners in virology, (onco-)immunology, ageing and immunosenescence, to assess the potential of immunomodulators, including kinase inhibitors licenced for other human use, to improve vaccine-induced immune responses and safety in older adults. ISOLDA partners have shown that these compounds may indeed restore key immunosenescent signatures. They will investigate ex-vivo signatures of immunological ageing and restoring potential of selected compounds on vaccine-induced immune responses against influenza virus, using PBMC from past and on-going adult and ageing human cohorts of influenza vaccinees. Cohorts of vaccinees and/or patients for tick-borne encephalitis, Middle-East respiratory syndrome and yellow fever are also uniquely available to ISOLDA to demonstrate broad applicability of the approach. The most promising compounds will be tested in in-vivo animal models for vaccination against these diseases. As a clinical proof of concept, ISOLDA will aim at improving efficacy of current seasonal influenza vaccines up to a tiered phase I clinical trial with a lead immunomodulator compound selected from the ex vivo and in vivo studies, that will be added to current vaccine formulations. ISOLDA will further build on new generation vaccines against MERS, such as replication-competent propagation-deficient replicons and MVA-MERS S recently developed by ISOLDA partners. Taken together, ISOLDA will address call SC1-BHC-14-2019, by providing innovative solutions to reduced efficacy and safety of preventive vaccines in the increasing population of older adults, against viral infections that have the highest impact in this age group.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores